# TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

> **NCT04967430** · PHASE3 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 763 (estimated)

## Conditions studied

- Sars-CoV2
- Covid19

## Interventions

- **DRUG:** Peginterferon Lambda-1A
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04967430
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-27
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-06-30
- **Target enrollment:** 763 (ESTIMATED)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967430, "TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04967430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*